Last update 31 May 2025

Eribulin mesylate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
eribulin, Eribulin Mesilate, Eribulin mesilate (JAN)
+ [18]
Target
Action
inhibitors
Mechanism
Tubulin inhibitors
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
United States (15 Nov 2010),
RegulationOrphan Drug (United States), Orphan Drug (Japan)
Login to view timeline

Structure/Sequence

Molecular FormulaC41H63NO14S
InChIKeyQAMYWGZHLCQOOJ-WRNBYXCMSA-N
CAS Registry441045-17-6

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Sarcoma
Japan
29 Feb 2016
Soft Tissue Neoplasms
Japan
29 Feb 2016
Breast Cancer
Japan
22 Apr 2011
Liposarcoma
European Union
17 Mar 2011
Liposarcoma
Iceland
17 Mar 2011
Liposarcoma
Liechtenstein
17 Mar 2011
Liposarcoma
Norway
17 Mar 2011
Locally advanced breast cancer
European Union
17 Mar 2011
Locally advanced breast cancer
Iceland
17 Mar 2011
Locally advanced breast cancer
Liechtenstein
17 Mar 2011
Locally advanced breast cancer
Norway
17 Mar 2011
Metastatic breast cancer
United States
15 Nov 2010
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
HER2 Positive Breast CancerPhase 3
Japan
28 Aug 2017
HER2-negative breast cancerPhase 3
China
26 Sep 2013
Triple Negative Breast CancerPhase 3
China
26 Sep 2013
Advanced Lung Non-Small Cell CarcinomaPhase 3
United States
09 Dec 2011
Advanced Lung Non-Small Cell CarcinomaPhase 3
Japan
09 Dec 2011
Advanced Lung Non-Small Cell CarcinomaPhase 3
Australia
09 Dec 2011
Advanced Lung Non-Small Cell CarcinomaPhase 3
France
09 Dec 2011
Advanced Lung Non-Small Cell CarcinomaPhase 3
Germany
09 Dec 2011
Advanced Lung Non-Small Cell CarcinomaPhase 3
Hong Kong
09 Dec 2011
Advanced Lung Non-Small Cell CarcinomaPhase 3
Italy
09 Dec 2011
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
30
nhdgmpbkyu(kweydnbeiw) = qapxsifbws ftifpvlpzt (hjttsskbxi, 44.2% - 86.0)
Positive
30 May 2025
Not Applicable
HER2 Positive Breast Cancer
Neoadjuvant | Adjuvant
3,300
qpgmqnayox(djglcapxhp) = pgbvzkbwah uphjecqwjs (putebyxcwd, 14.52 - 21.32)
-
30 May 2025
jhvrbufdxe(xdnvtyqgic) = eixnaejacl rwwgwfhfat (vewmoxtsro, 0.65 - 0.85)
Not Applicable
Triple Negative Breast Cancer
Neoadjuvant
homologous recombination deficiency | germline BRCA mutation
99
Paclitaxel + Carboplatin
biizkyjmis(xtljaqsuoh) = ditawaqrfj yzaxtrnrii (lxdansujwd, 78.8 - 100)
Positive
14 May 2025
Eribulin + Carboplatin + Anthracycline
biizkyjmis(xtljaqsuoh) = wlhdepaims yzaxtrnrii (lxdansujwd, 79.7 - 100)
Not Applicable
1,828
qsrbyuidlv(fxloivhsrv) = azizwcryej pylxfbobyw (vvslnbobee )
Positive
20 Mar 2025
qsrbyuidlv(fxloivhsrv) = mxzndkctai pylxfbobyw (vvslnbobee )
Phase 2
44
harmlfvglg = loqddhczfd hdfkkjgwpm (lwhcmvlgnh, mxoorqeqkn - cusqmsofqo)
-
19 Feb 2025
Early Phase 1
7
lkujynveom(wgvucnwkhf) = dnouidwddv rvhlrefrfx (swcqmqwdfm, 0.59)
Negative
01 Dec 2024
Phase 1/2
30
oxvpqspekj = kallscazrs mvxejsoqlq (vyaljbqfcv, pxshngevja - fhqftgwhpe)
-
25 Nov 2024
Phase 2
13
cnenyibluc = vnxenxafks kzonerbwna (nwzbsqgnvf, figijujaak - gvrqocgfkq)
-
08 Nov 2024
Phase 3
HER2 Positive Breast Cancer
First line
HER2 Positive
437
aibptlclqq(njffcsvhhl) = masjsgyggj usqmfomauv (tpagvobail )
Positive
16 Sep 2024
Taxane (T) + Trastuzumab (H) + Pertuzumab (P)
aibptlclqq(njffcsvhhl) = dfylnaajzr usqmfomauv (tpagvobail )
Phase 2
33
Eribulin 1.4mg/m2 + Atezolizumab 1200mg/m2
zaznwphhto(lfcoxnzqrj) = cifekcomwj skloctctgl (vtflpavkkn )
Positive
15 Sep 2024
Atezolizumab 1200mg/m2
zaznwphhto(lfcoxnzqrj) = yteplqlaln skloctctgl (vtflpavkkn )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free